← All companies
Monte Rosa Therapeutics, Inc.
GLUE - CIK 0001826457
Market cap$1.40 B
Rank#2377
SEC filings352
Monte Rosa Therapeutics, Inc. trades as GLUE and has a market capitalization of $1.40 B, making it the #2377 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $123.67M, up 63.5% from the prior year and net income of -$38.60M. This page tracks Monte Rosa Therapeutics, Inc. through 352 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$123.67MFY 2025
Net income (latest FY)-$38.60MFY 2025
Operating cash flow (latest FY)-$22.80MFY 2025
Total assets (latest FY)$448.66MFY 2025
Net margin-31.2%latest FY
Financial performance
Key statistics
- Market cap
- $1.40 B
- Share price (derived)market cap / shares outstanding
- $16.52
- Shares outstandingas of 2026-05-01
- 0.08B
- Total equityas of 2026-03-31
- $521.92M
- Return on equity
- -7.4%
- Cash & equivalentsas of 2026-03-31
- $159.86M
- Dividends paidFY 2025
- $0.00
- Current ratioas of 2026-03-31
- 9.54
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
Similar companies
The largest companies sharing Monte Rosa Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is Monte Rosa Therapeutics, Inc.'s market cap?
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $1.40 B as of 2026-06-11, ranking #2377 among US-listed companies.
How much revenue does Monte Rosa Therapeutics, Inc. make?
Monte Rosa Therapeutics, Inc. reported revenue of $123.67M for fiscal year 2025, an increase of 63.5% year over year.
Is Monte Rosa Therapeutics, Inc. profitable?
In its latest fiscal year Monte Rosa Therapeutics, Inc. reported a net loss of $38.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.